文献速递新发突发、热带与寄生虫病

乌干达北部季节性疟疾化学预防的药物计量学评估:SPAQ与DP对比

Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda.
PubMed 文献 · Clin Infect Dis · 2025-11-13

在乌干达北部开展前瞻性28天药物计量学评估,比较磺胺多辛-乙胺嘧啶-阿莫地喹(SPAQ)与双氢青蒿素-哌喹(DP)的季节性疟疾化学预防效果。结果显示SPAQ的临床和寄生虫学预防效力较低,而DP有效。

要点

  • SPAQ对全部疟原虫血症的保护效力为56%,对临床疟疾为60%。
  • DP对全部疟原虫血症的保护效力为84%,对临床疟疾为86%。
  • 所有基因分型的恶性疟分离株均携带Pfcrt K76(CVMNK单倍型),多数为五重Pfdhfr/dhps突变体。

核心结论

  • 在乌干达北部,SPAQ季节性疟疾化学预防的临床和寄生虫学预防效力较低,而DP有效。

研究设计与样本

  • 前瞻性28天药物计量学评估,在乌干达北部Karamoja两个村庄儿童接受SPAQ,第三个村庄儿童随机接受DP或无SMC,共入组1250名儿童。

主要发现

  • 基线qPCR疟原虫血症患病率为46%(575/1250),其中恶性疟85%,其他疟原虫(主要为卵形疟)25%。
  • 突破性寄生虫血症在DP组为7%(33/496),SPAQ组为31%(158/504),无药组为39%(98/250)。
  • 临床疟疾(均为恶性疟)在无药组为17%(42/250,1例重症),SPAQ组为8%(38/504,2例重症),DP组为2%(13/496)。
  • 调整后保护效力:SPAQ对全部疟原虫血症56%(95%CI 35-70%)、对恶性疟原虫血症46%(11-68%)、对临床疟疾60%(27-78%);DP分别为84%(77-89%)、86%(75-92%)、86%(74-92%)。
  • 所有260株基因分型的恶性疟分离株均为Pfcrt K76(CVMNK单倍型),多数为五重Pfdhfr/dhps突变体;去乙基阿莫地喹的暴露-反应关系强,磺胺多辛弱。

临床怎么用

  • 在SPAQ耐药高发地区,DP可作为季节性疟疾化学预防的有效替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal malaria chemoprevention (SMC) using monthly sulfadoxine-pyrimethamine-amodiaquine (SPAQ) is being deployed East Africa, where antimalarial drug resistance levels are high. Dihydroartemisinin-piperaquine (DP) is a potential alternative. METHODS: A prospective 28 day pharmacometric assessment of SMC was conducted in Karamoja, Northern Uganda. In two villages children received SPAQ and in a third were randomized to DP vs. no SMC The primary outcome was malaria infection defined by capillary blood sample qPCR positivity on day 28, or presentation with fever and slide or rapid test positivity after day 2. RESULTS: Baseline qPCR malaria parasitemia prevalence among 1250 enrolled children was 46% (575/1250); P. falciparum 85%, other malarias (mainly P. ovale) 25%. Breakthrough parasitemias occurred in 7% (33/496) of DP, 31% (158/504) of SPAQ, and 39% (98/250) of no drug recipients. Clinical malaria (all P. falciparum) developed in 17% of no drug (42/250; 1 severe), 8% of SPAQ (38/504; 2 severe) and 2% of DP (13/496) recipients. Adjusted protective efficacies against all malaria parasitemia, P. falciparum parasitemia, and clinical malaria were SPAQ; 56% (95%CI 35-70%), 46% (11-68%), and 60% (27-78%)and for DP; 84% (77-89%), 86% (75-92%) and 86% (74-92%) respectively. Some asymptomatic P. falciparum infections were not cleared by SPAQ. All 260 P. falciparum isolates genotyped were Pfcrt K76 (haplotype CVMNK, a marker of 4-aminoquinoline susceptibility) and most were quintuple Pfdhfr/dhps mutants (i.e. relatively SP resistant). The chemoprevention drug exposure-response relationship was strong for desethylamodiaquine, but weak for sulfadoxine. CONCLUSIONS: SPAQ SMC had low clinical and parasitological chemopreventive efficacy in Northern Uganda whereas dihydroartemisinin-piperaquine was effective.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bonnington C, Nuwa A, Theiss-Nyland K, et al. Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda. Clin Infect Dis. 2025. PMID: 41231725. doi:10.1093/cid/ciaf615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。